

EXHIBIT A
PENDING CLAIMS UPON ENTRY OF THE
INSTANT AMENDMENT
(filed October 28, 2002)

U.S. PATENT APPLICATION SERIAL NO. 09/606,909

28. A method for administration of a substance to a human subject, comprising delivering the substance into an intradermal compartment of the human subject's skin at a controlled volume and rate via a needle having a length sufficient to penetrate the intradermal space and an outlet at a depth within the intradermal space so that the substance is delivered and is distributed in the plasma.

29. A method for administration of a substance to a human subject, comprising delivering the substance into an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a higher plasma level.

30. A method for administration of a substance to a human subject, comprising delivering the substance into an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a faster onset of a detectable plasma level.

31. A method for the administration of a substance to a human subject, comprising delivering the substance into the an intradermal compartment of the human subject's skin, so that the substance is distributed systemically and has a pharmacokinetic profile similar to subcutaneous delivery of the substance, but with a higher bioavailability.

2. The method of Claim 28, wherein the needle is selected from the group consisting of microneedles, catheter needles, and injection needles.

3. The method of Claim 28, wherein a single needle is inserted.

4. The method of Claim 28, wherein multiple needles are inserted.

5. The method of any of Claims 28, 29, or 30, wherein the substance is a liquid delivered by pressure directly on the liquid.

6. The method of any of Claims 28, 29, or 30, wherein a hormone is delivered.

7. The method of Claim 6, wherein the hormone is selected from the group consisting of insulin and PTH.

10. The method of Claim 28, wherein the needle is about 300 mm to 2 mm long.

11. The method of Claim 28, wherein the needle is about 500 mm to 1 mm long.

12. The method of Claim 28, wherein the outlet is at a depth of about 250 mm to 2 mm when the needle is inserted.

13. The method of Claim 28, wherein the outlet is at a depth of about 750 mm to 1.5 mm when the needle is inserted.

14. The method of Claim 28, wherein the outlet has an exposed height of about 0 to 1 mm.

15. The method of Claim 28, wherein the outlet has an exposed height of about 0 to 300 mm.

16. The method of Claim 28, wherein the delivery rate or volume is controlled by spacing of multiple needles, needle diameter or number of needles.
